New York, NY–(Newsfile Corp. – March 18, 2024)- Powerful Medical has secured €7.5 million in funding from the European Innovation Council (EIC) for AI-powered heart attack diagnosis and future clinical validation. Selected from over 4,000 companies, the deep-tech medical device manufacturer’s clinical management platform PMcardio enables 35,000 healthcare professionals to diagnose cardiovascular disease with unparalleled accuracy and speed.

powerful medical

To view an expanded version of this graphic, please visit:
https://images.newsfilecorp.com/files/8871/201582_real_be2f8ebd-0eae-41fb-aa03-e916a8fba3e8_1.jpeg

Powerful Medical has distinguished itself in the competitive digital health landscape with breakthrough advances in medical diagnostics. The European Innovation Council (EIC) Accelerator Program highlights the venture among the world’s leading health technology initiatives, selecting Powerful Medical as one of the top four companies out of more than 4,000 applicants. Ranked in the top 0.1% of the same company. This recognition includes 2.5 million euro grant and 5 million euro investmentThis demonstrates the huge potential and transformative impact that Powerful Medical’s AI-powered solutions can bring to global healthcare. Further strengthening its financial footing, Powerful Medical has previously secured support from multiple funds backed by LifeX Ventures and the European Investment Bank (EIB), demonstrating a solid vote of confidence from a diverse group of investors. I am.

At the core of its mission, Powerful Medical introduces the PMcardio platform, a CE-certified medical device that leverages proprietary AI to analyze electrocardiograms (ECGs) with incredible accuracy. This platform can diagnose heart attacks, particularly obstructive myocardial infarction, significantly earlier and with twice the sensitivity compared to current standard of care. The platform’s diagnostic accuracy is even more important given that there are 50 million chest pain-related emergency room visits and 800,000 heart attacks each year in the U.S., of which one-third are initially misdiagnosed. It will be. The platform also identifies 38 other heart diseases and provides a broad set of tools for cardiovascular healthcare.

story continues

Powerful Medical, which has 35,000 registered medical professionals and tests 400,000 patients in the EU, is currently preparing to enter the US market. The company is nearing the final stages of receiving 510(k) FDA approval, a critical step in bringing the company’s key technology into the U.S. healthcare system. This movement is supported by pilot programs and research efforts in the U.S. in collaboration with leading medical institutions such as Stony Brook Medicine (New York), Minneapolis Heart Institute (Minnesota), and Hennepin Healthcare (Minnesota). Masu., among others. These efforts highlight not only the impact of Powerful Medical’s innovations, but also their potential to significantly improve longevity and quality of care for patients around the world.

A key contributing factor to Powerful Medical’s advancement is its extensive global research network, which enables it to conduct clinical trials across diverse patient groups. This aspect is highlighted by over 30 continuous validations that confirm the reliability and validity of the platform. These collaborations include renowned institutions such as the Aalst Cardiovascular Center, the largest heart disease center in Belgium, and the Sapienza University Hospital in Rome.

“By 2028, we aim to change the lives of more than 1 million heart attack patients. AI will enable this goal on a scale previously unrealistic, with unprecedented precision and early detection capabilities. By providing this, we can dramatically improve treatment outcomes and save lives.” – martin hermanCEO

Going forward, Powerful Medical envisions AI-powered diagnostics moving beyond traditional hospital settings, integrating into wearables and implantable devices, and moving into predictive medicine. This vision for the future aims to transform the management and treatment of cardiovascular disease, enabling earlier detection, better outcomes, and saving more lives.

“Our vision extends beyond today’s technology, paving the way for a future where AI not only supports but enhances patient care at every level.” – Dr. Robert HermanChief Medical Officer

As Powerful Medical begins its Series A funding, EIC Accelerator’s grants and investments validate the company’s vision and technology. For healthcare venture capital investors, this means an opportunity to invest in companies that are not only leading, but reshaping the future of cardiac care.

About Powerful Medical

Powerful Medical is at the forefront of the AI ​​revolution in healthcare, leading the fight against cardiovascular disease, the world’s leading cause of death. The company is setting new standards in cardiac care with its flagship product, PMcardio, his CE-certified medical device. This platform has an unparalleled ability to diagnose 39 cardiovascular diseases from any 12-lead ECG, outperforming traditional diagnostic methods. Already gaining significant traction in the EU, awaiting FDA 510(k) approval to enter the US market, and with multiple pilots underway in the US, Powerful Medical is poised for significant growth. is ready to accomplish. Its data-driven approach not only improves immediate clinical outcomes, but also paves the way for the future of predictive medicine. A powerful product backed by a strong research network and clinical validation. Medicine is about more than just transforming cardiac care. He’s saving lives one diagnosis at a time.

Communications and Media Company: Powerful Medical
Email: communication@powerfulmedical.com
Website: www.powerfulmedical.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/201582.